Autonomix Announces Issuance of U.S. Patent Covering Proprietary Catheter-Based Technology for the Treatment of Cancer Related Pain
16 avr. 2024 09h00 HE
|
Autonomix Medical, Inc.
Patent portfolio with over 100 patents, issued and pending, protects technology targeting a $100 billion market opportunity Company developing potential breakthrough two-fold technology that can...
Autonomix Announces Positive Findings from Preclinical Study Demonstrating Potential to Improve Renal Denervation
09 avr. 2024 08h30 HE
|
Autonomix Medical, Inc.
Preclinical study demonstrates potential of Autonomix technology to make renal denervation safer and more effective Ongoing advancement of sensing and ablation technologies toward proof-of-concept...
Autonomix to Participate in the Virtual Investor Lunch Break: The Team Behind the AMIX Ticker
08 avr. 2024 08h30 HE
|
Autonomix Medical, Inc.
Live webcast with members of the Autonomix management team, on Thursday, April 11th at 12:00 PM ET THE WOODLANDS, TX, April 08, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX)...
Autonomix to Present at the MedInvest Biotech & Pharma Investor Conference
27 mars 2024 09h00 HE
|
Autonomix Medical, Inc.
Live webcast presentation on Thursday, April 4th at 3:55 PM ET THE WOODLANDS, TX, March 27, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a...
Autonomix (NASDAQ: AMIX) to Present at the Benzinga Virtual Healthcare Summit 2024
20 mars 2024 08h05 HE
|
Autonomix Medical, Inc.
Live webcast presentation on Wednesday, March 20th at 11:50 AM ET THE WOODLANDS, TX, March 20, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a...
Autonomix Appoints Jennifer Cook as Chief Business Officer
19 mars 2024 08h45 HE
|
Autonomix Medical, Inc.
Proven executive with 28 years of success building winning B2C & B2B businesses, brands, and teams for premier consumer, healthcare, and medical technology brands THE WOODLANDS, TX, March 19,...
Autonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
14 mars 2024 08h15 HE
|
Autonomix Medical, Inc.
First trial to ever evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, March 14, 2024 (GLOBE NEWSWIRE) --...
Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
06 mars 2024 08h00 HE
|
Autonomix Medical, Inc.
First trial to ever evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, March 06, 2024 (GLOBE NEWSWIRE) --...
Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial
29 févr. 2024 08h30 HE
|
Autonomix Medical, Inc.
Proof-of-concept (PoC) human clinical trial targeting multi-billion-dollar pancreatic cancer market through transvascular RF ablation Agreements represent final steps needed in order to commence...
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Lunch Break: The Autonomix Opportunity
23 févr. 2024 08h50 HE
|
Autonomix Medical, Inc.
Live webcast with Lori Bisson, Chief Executive Officer of Autonomix, on Thursday, February 29th at 12:00 PM ET THE WOODLANDS, TX, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:...